{
    "clinical_study": {
        "@rank": "126190", 
        "arm_group": [
            {
                "arm_group_label": "Part I, Cohort A (Pembro + Paclitaxel [Pa] + Carboplatin [C])", 
                "arm_group_type": "Experimental", 
                "description": "pembrolizumab (2 or 10 mg/kg) + paclitaxel (200 mg/m^2) + carboplatin (6 mg/mL/minute)"
            }, 
            {
                "arm_group_label": "Part I, Cohort B (Pembro + Pa + C+ Bevacizumab [B])", 
                "arm_group_type": "Experimental", 
                "description": "pembrolizumab (2 or 10 mg/kg) + paclitaxel (200 mg/m^2) + carboplatin (6 mg/mL/minute) + bevacizumab (15 mg/kg)"
            }, 
            {
                "arm_group_label": "Part I, Cohort C (Pembro + Pemetrexed [Pe] + C)", 
                "arm_group_type": "Experimental", 
                "description": "pembrolizumab (2 or 10 mg/kg) + Pemetrexed (500 mgm^2) + Carboplatin (5 mg/mL/min)"
            }, 
            {
                "arm_group_label": "Part I, Cohort D (Pembro + Ipilimumab [I])", 
                "arm_group_type": "Experimental", 
                "description": "pembrolizumab ( (2 or 10 mg/kg) + Ipilimumab (0.3, 1, or 3 mg/kg)"
            }, 
            {
                "arm_group_label": "Part I, Cohort E (Pembro + Erlotinib)", 
                "arm_group_type": "Experimental", 
                "description": "pembrolizumab (2 or 10 mg/kg) + Erlotinib (150 mg)"
            }, 
            {
                "arm_group_label": "Part I, Cohort F (Pembro + Gefitinib)", 
                "arm_group_type": "Experimental", 
                "description": "pembrolizumab (2 or 10 mg/kg) + Gefitinib (250 mg)"
            }, 
            {
                "arm_group_label": "Part II, Cohort G (Pembro + chemotherapy)", 
                "arm_group_type": "Experimental", 
                "description": "Cohort G1: selected dose of pembrolizumab and chemotherapies from cohorts A,B, and C. Cohort G2: there may be an optional Cohort G2, depending on the results of G1."
            }, 
            {
                "arm_group_label": "Part II, Cohort H (Pembro + I)", 
                "arm_group_type": "Experimental", 
                "description": "selected dose of pembrolizumab and ipilimumab from cohort D"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine safety, tolerability, and efficacy of\n      pembrolizumab (MK-3475) in combination with chemotherapy or immunotherapy in participants\n      with unresectable or metastatic non-small cell lung cancer (NSCLC)."
        }, 
        "brief_title": "A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)", 
        "completion_date": {
            "#text": "June 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small Cell Lung Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Stage IIIb/IV NSCLC\n\n          -  at least one radiographically measurable lesion\n\n          -  performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)\n             Performance Status\n\n          -  Females are not pregnant nor of child-bearing potential\n\n          -  if of childbearing potential, females must be willing to use two adequate barrier\n             methods throughout the study\n\n          -  males with a female partner(s) of child-bearing potential must agree to use two\n             adequate barrier methods throughout the trial\n\n        Exclusion Criteria:\n\n          -  currently participating or has participated in a study of an investigational agent or\n             using an investigational device within 30 days of administration of pembrolizumab\n\n          -  expected to require any other form of antineoplastic therapy while on study\n\n          -  is on chronic systemic steroid therapy or on any other form of immunosuppressive\n             medication\n\n          -  has received a live-virus vaccination within 30 days of planned treatment start\n\n          -  history of diverticulitis, intra-abdominal abscess, gastrointestinal (GI)\n             obstruction, abdominal carcinomatosis which are known risks factors for bowel\n             perforation\n\n          -  history of a hematologic malignancy, primary brain tumor or sarcoma, or of another\n             primary solid tumor, unless the participant has undergone potentially curative\n             therapy with no evidence of that disease for 5 years\n\n          -  active central nervous system (CNS) metastases and/or carcinomatous meningitis\n\n          -  severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb)\n\n          -  active autoimmune disease or a documented history of autoimmune disease or syndrome\n             that requires systemic steroids or immunosuppressive agents\n\n          -  prior treatment with any other anti-programmed cell death protein-1 (anti-PD-1), or\n             PD Ligand-1 (PD-L1) or PD Ligand-2 (PD-L2) agent or an antibody targeting other\n             immuno-regulatory receptors or mechanisms\n\n          -  active infection requiring therapy\n\n          -  history of Human Immunodeficiency Virus (HIV)\n\n          -  active Hepatitis B or C.\n\n          -  symptomatic ascites or pleural effusion\n\n          -  pneumonitis that has required a course of oral steroids to assist with recovery, or a\n             history of interstitial lung disease\n\n          -  pregnant or breastfeeding, or expecting to conceive or father children within the\n             projected duration of the study\n\n          -  psychiatric disorders and substance (drug/alcohol) abuse"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "320", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02039674", 
            "org_study_id": "3475-021"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Part I, Cohort A (Pembro + Paclitaxel [Pa] + Carboplatin [C])", 
                    "Part I, Cohort B (Pembro + Pa + C+ Bevacizumab [B])", 
                    "Part I, Cohort C (Pembro + Pemetrexed [Pe] + C)", 
                    "Part I, Cohort D (Pembro + Ipilimumab [I])", 
                    "Part I, Cohort E (Pembro + Erlotinib)", 
                    "Part I, Cohort F (Pembro + Gefitinib)", 
                    "Part II, Cohort G (Pembro + chemotherapy)", 
                    "Part II, Cohort H (Pembro + I)"
                ], 
                "description": "intravenously (IV) every 3 weeks (Q3W) on Day 1 of each cycle prior to chemo/immunotherapy", 
                "intervention_name": "Pembrolizumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part I, Cohort A (Pembro + Paclitaxel [Pa] + Carboplatin [C])", 
                    "Part I, Cohort B (Pembro + Pa + C+ Bevacizumab [B])", 
                    "Part II, Cohort G (Pembro + chemotherapy)"
                ], 
                "description": "IV Q3W on Day 1 of each cycle", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part I, Cohort A (Pembro + Paclitaxel [Pa] + Carboplatin [C])", 
                    "Part I, Cohort B (Pembro + Pa + C+ Bevacizumab [B])", 
                    "Part I, Cohort C (Pembro + Pemetrexed [Pe] + C)", 
                    "Part II, Cohort G (Pembro + chemotherapy)"
                ], 
                "description": "IV Q3W on Day 1 of each cycle", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Part I, Cohort B (Pembro + Pa + C+ Bevacizumab [B])", 
                "description": "IV Q3W on Day 1 of each cycle", 
                "intervention_name": "Bevacizumab", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Part I, Cohort C (Pembro + Pemetrexed [Pe] + C)", 
                "description": "IV Q3W on Day 1 of each cycle", 
                "intervention_name": "Pemetrexed", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part I, Cohort D (Pembro + Ipilimumab [I])", 
                    "Part II, Cohort H (Pembro + I)"
                ], 
                "description": "IV Q3W on Day 1 of each cycle", 
                "intervention_name": "Ipilimumab", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Part I, Cohort E (Pembro + Erlotinib)", 
                "description": "Orally (po) daily (QD)", 
                "intervention_name": "Erlotinib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Part I, Cohort F (Pembro + Gefitinib)", 
                "description": "po QD", 
                "intervention_name": "Gefitinib", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Pemetrexed", 
                "Bevacizumab", 
                "Gefitinib", 
                "Carboplatin", 
                "Paclitaxel", 
                "Erlotinib"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "PD-1", 
            "PD1", 
            "Programmed Cell Death-1", 
            "Programmed Cell Death 1"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Call for Information (Investigational Site 0005)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }, 
                    "name": "Call for Information (Investigational Site 0013)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Call for Information (Investigational Site 0007)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "Call for Information (Investigational Site 0003)"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "8", 
        "official_title": "A Phase I/II Study of MK-3475 (SCH900475) in Combination With Chemotherapy or Immunotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_official": {
            "affiliation": "Merck Sharp & Dohme Corp.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Part II, Cohort G: Progression-Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Part II, Cohort G: Objective Response Rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Part II, Cohort H: Overall Response Rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Part I, All Cohorts: the recommended Phase II dose for pembrolizumab in combination with chemotherapy or immunotherapy", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02039674"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}